Annual EBITDA
-$38.13 M
-$23.01 M-152.18%
31 December 2023
Summary:
SAB Biotherapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$38.13 million, with the most recent change of -$23.01 million (-152.18%) on 31 December 2023. During the last 3 years, it has fallen by -$59.27 million (-280.43%). SABS annual EBITDA is now -280.43% below its all-time high of $21.14 million, reached on 31 December 2020.SABS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$9.30 M
-$3.12 M-50.39%
30 September 2024
Summary:
SAB Biotherapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$9.30 million, with the most recent change of -$3.12 million (-50.39%) on 30 September 2024. Over the past year, it has dropped by -$5.26 million (-129.90%). SABS quarterly EBITDA is now -609.11% below its all-time high of $1.83 million, reached on 31 March 2022.SABS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$40.29 M
-$5.26 M-15.01%
30 September 2024
Summary:
SAB Biotherapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$40.29 million, with the most recent change of -$5.26 million (-15.01%) on 30 September 2024. Over the past year, it has dropped by -$17.15 million (-74.14%). SABS TTM EBITDA is now -2386.39% below its all-time high of $1.76 million, reached on 31 March 2021.SABS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SABS EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -152.2% | -129.9% | -74.1% |
| 3 y3 years | -280.4% | -160.8% | -821.5% |
| 5 y5 years | - | - | - |
SABS EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -280.4% | at low | -609.1% | +57.4% | -821.5% | at low |
| 5 y | 5 years | -280.4% | at low | -609.1% | +57.4% | -2386.4% | at low |
| alltime | all time | -280.4% | at low | -609.1% | +57.4% | -2386.4% | at low |
SAB Biotherapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$9.30 M(+50.4%) | -$40.29 M(+15.0%) |
| June 2024 | - | -$6.19 M(+108.7%) | -$35.03 M(+0.8%) |
| Mar 2024 | - | -$2.96 M(-86.4%) | -$34.76 M(-8.8%) |
| Dec 2023 | -$38.13 M(+152.2%) | -$21.83 M(+439.5%) | -$38.13 M(+64.8%) |
| Sept 2023 | - | -$4.05 M(-31.6%) | -$23.14 M(-8.1%) |
| June 2023 | - | -$5.91 M(-6.7%) | -$25.18 M(+8.1%) |
| Mar 2023 | - | -$6.34 M(-7.3%) | -$23.29 M(+54.0%) |
| Dec 2022 | -$15.12 M | -$6.84 M(+12.2%) | -$15.12 M(-20.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2022 | - | -$6.10 M(+51.8%) | -$19.11 M(+15.2%) |
| June 2022 | - | -$4.02 M(-319.7%) | -$16.58 M(+9.6%) |
| Mar 2022 | - | $1.83 M(-116.9%) | -$15.13 M(-0.4%) |
| Dec 2021 | -$15.20 M(-171.9%) | -$10.82 M(+203.4%) | -$15.20 M(+247.5%) |
| Sept 2021 | - | -$3.57 M(+39.0%) | -$4.37 M(+443.2%) |
| June 2021 | - | -$2.57 M(-245.7%) | -$804.90 K(-145.7%) |
| Mar 2021 | - | $1.76 M | $1.76 M |
| Dec 2020 | $21.14 M(-356.7%) | - | - |
| Dec 2019 | -$8.23 M | - | - |
FAQ
- What is SAB Biotherapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for SAB Biotherapeutics?
- What is SAB Biotherapeutics annual EBITDA year-on-year change?
- What is SAB Biotherapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for SAB Biotherapeutics?
- What is SAB Biotherapeutics quarterly EBITDA year-on-year change?
- What is SAB Biotherapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for SAB Biotherapeutics?
- What is SAB Biotherapeutics TTM EBITDA year-on-year change?
What is SAB Biotherapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of SABS is -$38.13 M
What is the all time high annual EBITDA for SAB Biotherapeutics?
SAB Biotherapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is $21.14 M
What is SAB Biotherapeutics annual EBITDA year-on-year change?
Over the past year, SABS annual earnings before interest, taxes, depreciation & amortization has changed by -$23.01 M (-152.18%)
What is SAB Biotherapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of SABS is -$9.30 M
What is the all time high quarterly EBITDA for SAB Biotherapeutics?
SAB Biotherapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $1.83 M
What is SAB Biotherapeutics quarterly EBITDA year-on-year change?
Over the past year, SABS quarterly earnings before interest, taxes, depreciation & amortization has changed by -$5.26 M (-129.90%)
What is SAB Biotherapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of SABS is -$40.29 M
What is the all time high TTM EBITDA for SAB Biotherapeutics?
SAB Biotherapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $1.76 M
What is SAB Biotherapeutics TTM EBITDA year-on-year change?
Over the past year, SABS TTM earnings before interest, taxes, depreciation & amortization has changed by -$17.15 M (-74.14%)